[
  {
    "ts": "2025-12-08T01:00:00+00:00",
    "headline": "RYBREVANT速 (amivantamab-vmjw) plus LAZCLUZE速 (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study",
    "summary": "Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed amivantamab plus lazertinib led to a clinically meaningful OS improvement in the first-line treatment of Asian patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. Median OS fo",
    "url": "https://finance.yahoo.com/news/rybrevant-amivantamab-vmjw-plus-lazcluze-010000989.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "cfd7bf14-b9fd-3213-a8c8-86a28e143e05",
      "content": {
        "id": "cfd7bf14-b9fd-3213-a8c8-86a28e143e05",
        "contentType": "STORY",
        "title": "RYBREVANT速 (amivantamab-vmjw) plus LAZCLUZE速 (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study",
        "description": "",
        "summary": "Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed amivantamab plus lazertinib led to a clinically meaningful OS improvement in the first-line treatment of Asian patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. Median OS fo",
        "pubDate": "2025-12-08T01:00:00Z",
        "displayTime": "2025-12-08T01:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/69c6b64bb2bb88dcb0943d1efbea3054",
          "originalWidth": 400,
          "originalHeight": 37,
          "caption": "Johnson & Johnson logo (PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QH2dFsQ9Hz2iJanf7Rh._Q--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/69c6b64bb2bb88dcb0943d1efbea3054.cf.webp",
              "width": 400,
              "height": 37,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ksTJ99k4dB3NfNRyqXUbYg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/69c6b64bb2bb88dcb0943d1efbea3054.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rybrevant-amivantamab-vmjw-plus-lazcluze-010000989.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rybrevant-amivantamab-vmjw-plus-lazcluze-010000989.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]